Low dose aminoglutethimide without hydrocortisone for the treatment of advanced postmenopausal breast cancer

European Journal of Cancer and Clinical Oncology

Volumn 25, Issue 2, 1989, Pages 369-376

  Bruning, P F ^a   Bonfrer, J M G ^a   Hart, A A M ^a   van der Linden, E ^a   de Jong Bakker, M ^a   Moolenaar, A J ^b   Nooijen, W J ^a  

^a ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

^b LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE;

ADULT; AGED; BREAST CANCER; DROWSINESS; FEMALE; HUMAN; MAJOR CLINICAL STUDY; METASTASIS; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; POSTMENOPAUSE;

17-HYDROXYPROGESTERONE; AMINOGLUTETHIMIDE; ANDROSTENEDIONE; BREAST NEOPLASMS; DRUG EVALUATION; ESTRADIOL; ESTRONE; FEMALE; HUMAN; HYDROCORTISONE; HYDROXYPROGESTERONES; MENOPAUSE; MIDDLE AGE; RECEPTORS, ESTROGEN;

EID: 0024501357     PISSN: 02775379     EISSN: None     Source Type: Journal    
DOI: 10.1016/0277-5379(89)90032-1     Document Type: Article

References (30)

1. Aminoglutethimide (Elipten-CIBA) as an inhibitor of adrenal stereoidogenesis
2. Preliminary trial of aminoglutethimide in breast cancer
3. Medical adrenalectomy using aminoglutethimide and dexamethasone in advanced breast cancer
4. Medical adrenalectomy with aminoglutethimide
5. Aminoglutethimide inhibits extraglandular estrogen production in postmenopausal women with breast carcinoma
6. Inhibition of aromatase as treatment of breast carcinoma in postmenopausal women
7. Adrenal suppression with aminoglutethimide I. Differential effect of aminoglutethimide on plasma androstenedione and estrogen levels
8. 5-steroids in postmenopausal women treated for breast carcinoma
9. Stereoselective inhibition of aromatase by enantiomers of aminoglutethimide
10. Effective inhibition by low dose aminoglutethimide of peripheral aromatization in postmenopausal breast cancer patients
11. Effects of aminoglutethimide on adrenal secretion
12. Endocrine effects of low dose aminoglutethimide alone in advanced postmenopausal breast cancer
13. Low dose aminoglutethimide in treatment of advanced breast cancer
14. A randomized trial comparing surgical adrenalectomy with aminoglutethimide plus hydrocortisone in women with advanced breast cancer
15. Assessment of response to therapy in advanced breast cancer
16. Influence of ACTH on aminoglutethimide induced reduction of plasma steroids in postmenopausal breast cancer
17. Pros and cons of aminoglutethimide for advanced postmenopausal breast cancer
18. Tamoxifen versus aminoglutethimide versus combined Tamoxifen and aminoglutethimide in the treatment of advanced breast carcinoma
19. Randomized trial of aminoglutethimide versus Tamoxifen in metastatic breast cancer
20. A comparative trial of transsphenoidal hypophysectomy and estrogen suppression with aminoglutethimide in advanced breast cancer
21. 19 steroids by human breast cancers
22. Biological significance of aromatase activity in human breast tumors
23. Aromatase activity in primary and metastatic human breast cancer
24. Steroid hormone profiles in women treated with aminoglutethimide for metastatic carcinoma of the breast
25. A comparison of the endocrine effects of low dose aminoglutethimide with and without hydrocortisone in postmenopausal breast cancer patients
26. Aminoglutethimide in advanced breast cancer: clinical results of a French multicenter randomized trial comparing 500 mg and 1 g/day
27. Aminoglutethimide in the treatment of advanced breast cancer
28. New aspects of hormonal treatment of metastatic breast cancer
29. Primary hypothyroidism in breast cancer patients with irradiated supraclavicular lymph nodes